IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis.

The mechanisms underlying the failure to contain the growth of Leishmania parasites in human visceral leishmaniasis (VL) are not understood. L donovani amastigotes were quantified in cultured splenic aspirate cells to assess the function of IL-10 in lesional tissue ex vivo. In 67 patients with active VL, IL-10 neutralization promoted parasite killing in 73% and complete clearance in 30%, while 18% had more parasites and 9% did not change. The splenic cells secreted increased levels of both tumor necrosis factor α (TNFα) and interferon γ (IFNγ) under IL-10-neutralizing conditions. These findings provide direct support for targeting IL-10 as an approach to therapy in human VL.

[1]  R. Sabat,et al.  Biology of interleukin-10. , 2010, Cytokine & growth factor reviews.

[2]  H. Jessen,et al.  IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. , 2009, Blood.

[3]  H. Bang,et al.  Tuberculosis Is Associated with a Down-Modulatory Lung Immune Response That Impairs Th1-Type Immunity1 , 2009, The Journal of Immunology.

[4]  J. Sattabongkot,et al.  Plasmodium vivax parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells , 2008, European journal of immunology.

[5]  E. Riley,et al.  IL-10: The Master Regulator of Immunity to Infection , 2008, The Journal of Immunology.

[6]  D. Sacks,et al.  Interleukin-10 and the pathogenesis of human visceral leishmaniasis. , 2007, Trends in immunology.

[7]  S. Sundar,et al.  Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis , 2007, The Journal of experimental medicine.

[8]  P. Bejon,et al.  Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage Plasmodium falciparum Correlate with Parasitological and Clinical Outcomes , 2006 .

[9]  S. Sundar,et al.  Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. , 2005, The Lancet. Infectious diseases.

[10]  K. Flanders,et al.  Antagonizing Deactivating Cytokines To Enhance Host Defense and Chemotherapy in Experimental Visceral Leishmaniasis , 2005, Infection and Immunity.

[11]  H. Murray,et al.  Immunoenhancement Combined with Amphotericin B as Treatment for Experimental Visceral Leishmaniasis , 2003, Antimicrobial Agents and Chemotherapy.

[12]  P. Melby,et al.  Animal models for the analysis of immune responses to leishmaniasis. , 2015, Current protocols in immunology.

[13]  V. Boussiotis,et al.  IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. , 2000, The Journal of clinical investigation.

[14]  S. Reed,et al.  Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. , 1994, Journal of immunology.

[15]  Mohamed,et al.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections. , 1993, The Journal of clinical investigation.

[16]  E. Coligan.  Current protocols in immunology , 1991 .